









Markets
/
Stocks
/
nasdaq-sskn
/

STRATA Skin Sciences Inc

SSKN

1.780USD

+0.080+4.71%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

7.42MMarket Cap

LossP/E TTM



STRATA Skin Sciences Inc

1.780

+0.080+4.71%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of STRATA Skin Sciences Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

STRATA Skin Sciences Inc's Score

Industry at a Glance

Industry Ranking

103 / 210

Overall Ranking

224 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.000

Target Price

+365.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

STRATA Skin Sciences Inc Highlights

StrengthsRisks

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

Growing

The company is in a growing phase, with the latest annual income totaling USD 33.56M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 33.56M.

Overvalued

The company’s latest PE is -0.60, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.02M shares, increasing 7.56% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 98.03K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 16.43.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.11, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 7.66M, representing a year-over-year decrease of 9.15%, while its net profit experienced a year-over-year decrease of 2414.14%.

Score

Industry at a Glance

Previous score

7.11

Change



Financials

5.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.73

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.93

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.18

Key Metrics

Free cash flow

No Data

STRATA Skin Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.23, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.60, which is -18.24% below the recent high of -0.49 and -1289.88% above the recent low of -8.32.

Score

Industry at a Glance

Previous score

7.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 103/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for STRATA Skin Sciences Inc is 8.00, with a high of 12.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

8.000

Target Price

+365.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Strata Skin Sciences Inc

SSKN

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.21, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 2.40 and the support level at 1.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.59

Change

0.62

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Sell

RSI(14)

46.354

Neutral

STOCH(KDJ)(9,3,3)

23.930

Neutral

ATR(14)

0.216

Low Volatility

CCI(14)

-60.061

Neutral

Williams %R

77.632

Sell

TRIX(12,20)

-0.348

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.754

Buy

MA10

1.742

Buy

MA20

1.792

Sell

MA50

1.856

Sell

MA100

1.981

Sell

MA200

2.313

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 57.24%, representing a quarter-over-quarter decrease of 15.84%. The largest institutional shareholder is James Simons, holding a total of 98.03K shares, representing 1.86% of shares outstanding, with 24.89% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Accelmed Growth Partners Management Ltd

1.44M

22NW, LP

537.00K

Nantahala Capital Management, LLC

403.92K

Lincoln Alternative Strategies LLC

365.85K

Heights Capital Management, Inc.

365.85K

Renaissance Technologies LLC

Star Investors

98.03K

-3.73%

The Vanguard Group, Inc.

Star Investors

84.63K

Rubinstein (Samuel)

19.86K

+983.47%

Geode Capital Management, L.L.C.

18.19K

-0.42%

MGO One Seven LLC

17.14K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.33, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.